Designs to determine the impact of Ab resistance How do we correctly measure the outcomes of antibiotic resistance?

Slides:



Advertisements
Similar presentations
Surveillance of nosocomial infections Johnny, Courtesy, Brocolli.
Advertisements

Antibiotic Pressure and Resistance in Bacteria Sarmistha B. Hauger M.D. Director, Pediatric Infectious Disease Childrens Hospital of Austin Austin, Texas.
British Society for Antimicrobial Chemotherapy Symposium Resistance and treatment issues in Blood Stream Infection: S.aureus Alasdair MacGowan BCARE University.
Pablo M. Bedano M.D. Community Regional Cancer Care.
1 Case-Control Study Design Two groups are selected, one of people with the disease (cases), and the other of people with the same general characteristics.
1 Issues in Selection of Deltas in Non-Inferiority Trials : Acute Bacterial Meningitis and Hospital- Acquired Pneumonia John H. Powers, M.D. Medical Officer.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence May–June 2010.
Pneumonia & Respiratory Tract Infection: Antibiotic risk for Clostridium difficile Kieran Hand*, Adil Ahmed †, Adriana Basarab ¶, Whitney Chow †, Nick.
Antibiotic Resistance why do we care? Thursday 1/10/2008.
Evaluating Whether Interventions on the Use of Antibiotics Work to Decrease Resistance Chris Ford Regina Joice 1/18/08.
What intervention on the use or dosing of antibiotics work to decrease resistance? Jan. 18, 2007 Sung-Ching Pan.
What do case-control studies tell us about risk factors for antibiotic resistance? Christie Y. Jeon EPI502 Jan 22 nd, 2008.
Journal Club Alcohol and Health: Current Evidence July–August 2004.
What ecological studies can & can’t tell us Justin O’Hagan 2 nd year Epi Doctoral Student.
The Redesigned National Hospital Discharge Survey National Center for Health Statistics Division of Health Care Statistics Hospital Care Team Last Updated:
Early results from implementation of a novel perioperative geriatric service in an acute surgical unit Dr Lauren Styan, Dr Skyle Murphy, Dr Aisling Fleury,
Methicillin-Resistant Staphylococcus aureus Infections in California Hospital Patients, 1999 – 2006 Mary Tran, PhD, MPH Niya Fong, BS Microbiology California.
DOES MEDICARE SAVE LIVES?
Study Design / Data: Case-Control, Descriptives Basic Medical Statistics Course: Module C October 2010 Wilma Heemsbergen
Cohort Study.
1 Lecture 20: Non-experimental studies of interventions Describe the levels of evaluation (structure, process, outcome) and give examples of measures of.
The Effect of Chest Wall Injuries on Morbidity and Mortality in the Elderly Cierra Jenkins 1, Dr. Ronald Benenson M.D 1,2. 1 Department of Biological Sciences,
Concepts of Interaction Matthew Fox Advanced Epi.
Projects for Homoeopathic Units working under Homoeopathic Wing Dr. Mridula Pandey id :
Systematic Review on the Effectiveness of Handwashing -interim report- Hiroshi Ikai Stephanie Smith Allison McGeer Department of Infection Control, Mount.
Epidemiology The Basics Only… Adapted with permission from a class presentation developed by Dr. Charles Lynch – University of Iowa, Iowa City.
AETIOLOGY Case control studies (also RCT, cohort and ecological studies)
Economic Burden and Health Consequences of Antibiotic Resistance in Patients at a Tertiary Care Hospital, Vellore, South India Sujith J Chandy (1,2), Thomas.
Acute Bacterial Rhinosinusitis. Brief Background Typically follows viral infection Dx is by clinical manifestations Streptococcus pneumoniae, Haemophilus.
CHP400: Community Health Program- lI Research Methodology STUDY DESIGNS Observational / Analytical Studies Case Control Studies Present: Disease Past:
Evidence Based Medicine
ECON ECON Health Economic Policy Lab Kem P. Krueger, Pharm.D., Ph.D. Anne Alexander, M.S., Ph.D. University of Wyoming.
Thank you for viewing this presentation. We would like to remind you that this material is the property of the author. It is provided to you by the ERS.
Approach To Pneumonia. Pneumonia Importance Mechanism Classification & its benefit Diagnosis Treatment.
Causation ? Tim Wiemken, PhD MPH CIC Assistant Professor Division of Infectious Diseases University of Louisville, Kentucky.
Time – Immortal Bias in the analysis of “Influenza and COPD Mortality Protection as Pleiotropic, Dose-dependent effects of statins” by Floyd J, Frost et.
Thank you for viewing this presentation. We would like to remind you that this material is the property of the author. It is provided to you by the ERS.
RBC transfusions in critically ill patients TMR Journal Club March 1, 2007 Maggie Constantine.
Systematic review + meta-analysis: 69 (quasi-)randomised trials: N=7,863 pts with sepsis: any BL monoTx vs any combination of BL + AG: N (studies) : same.
Design and Analysis of Clinical Study 2. Bias and Confounders Dr. Tuan V. Nguyen Garvan Institute of Medical Research Sydney, Australia.
Lecture 9: Analysis of intervention studies Randomized trial - categorical outcome Measures of risk: –incidence rate of an adverse event (death, etc) It.
The Association between blood glucose and length of hospital stay due to Acute COPD exacerbation Yusuf Kasirye, Melissa Simpson, Naren Epperla, Steven.
Case-Control Studies Abdualziz BinSaeed. Case-Control Studies Type of analytic study Unit of observation and analysis: Individual (not group)
The Health Roundtable Postoperative IV Antibiotic Therapy for Children with Complicated Appendicitis: A Propensity Score-Matched Observational Study Presenter:
CROSS SECTIONAL STUDIES
Which Beta-Blocker is Best for Patients with Heart Failure? Summary and Comment by Joel M. Gore, MD Published in Journal Watch Cardiology December 17,
Research Design Evidence Based Medicine Concepts and Glossary.
Treatment duration and outcomes for male urinary tract infection (UTI) Retrospective review of 33,336 patients with index UTI from Veterans Affairs database.
MICROBIOLOGICAL EPIDEMIOLOGY OF RESPIRATORY SPECIMENS IN ICU PATIENTS Dr Farooq Cheema, Dr Waseem Tariq, Dr Raja Ishtiaq, Dr Tabassum Qureshi, Dr Vincent.
Comparative Effectiveness of Different Skin Antiseptic Agents in Reducing Surgical Site Infections Timo W. Hakkarainen, E. Patchen Dellinger, Rafael Alfonso-Cristancho.
Diamantis P. Kofteridis, Christina Alexopoulou, Antonios Valachis, Sofia Maraki, Dimitra Dimopoulou Clinical Infectious Diseases 2010; 51(11):1238–1244.
PANDHARIPANDE PP ET AL. N ENGL J MED 2013; 369: Long-Term Cognitive Impairment after Critical Illness.
Acute Renal Failure in HIV- Infected Individuals Greatly Increases Risk for In-Hospital Mortality Slideset on: Wyatt CM, Arons RR, Klotman PE, Klotman.
Purpose of Epi Studies Discover factors associated with diseases, physical conditions and behaviors Identify the causal factors Show the efficacy of intervening.
Case Control study. An investigation that compares a group of people with a disease to a group of people without the disease. Used to identify and assess.
JAMA Internal Medicine May 2015 Volume 175, Number5 R1 조한샘 / Prof. 이창균.
Clostridium difficile infection (CDI) in the ICU and Clostridium difficile outcomes in the PROSPECT Main Trial Erick Duan MD FRCPC Presented at the CCCTG.
The comparative self-controlled case series (CSCCS)
Present: Disease Past: Exposure
Insights Using Data from California Richard H. White MD
Vaccine Efficacy, Effectiveness and Impact
Biostatistics Case Studies 2016
Donald E. Cutlip, MD Beth Israel Deaconess Medical Center
The ‘bed location lottery’: the MDRO status of the prior bed occupant affects the risk of acquisition Jon Otter, PhD Scientific Director, Healthcare, Bioquell.
Empirical antibiotic treatment algorithm for hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP). Empirical antibiotic treatment algorithm.
Epidemiology MPH 531 Analytic Epidemiology Case control studies
Pneumococcal Polysaccharide (PV) Vaccine Failures among HIV-infected Veterans Compared to Non-HIV-infected controls. Maria C. Rodriguez-Barradas, MD.
E. Tacconelli  Clinical Microbiology and Infection 
Effect Modifiers.
Presentation transcript:

Designs to determine the impact of Ab resistance How do we correctly measure the outcomes of antibiotic resistance?

Measuring impact of resistance - methodological issues : Which study designs are appropriate? Case control vs. Cohort studies. what is the right control? What are we measuring? Confounders. What do we have to adjust for? Defining the outcomes?

Study designs used to define the impact of Ab resistance: Descriptive studies Case-control studies Cohort studies Meta-analysis Mathematical models

Descriptive studies Emergence of MDR19A pneumococcal strain… Pichichero JAMA 2007 What type of a study is this? Prospective cohort study. Cohort study: –A cohort – a group of people who share a common experience / condition –Compare exposure of interest and follow to measure outcomes in exposed vs. non- exposed.

Emergence of MDR19A / Pichichero JAMA 2007 Trend in time: –More non-VT –More non-VT resistance –More total Sp resistance –More 19A among non- VT 1816 AOM 375 AOM included 211 tympanocentesis 59 S. pneumonia 9 19A strain

Emergence of MDR19A / Pichichero JAMA 2007 What are the bad outcomes of the resistant strain? Can we determine that the bad outcome is a result of the resistance?

19A MDR S. pneumoniae; an emerging pathogen Resistant to all FDA approved antibiotics (for AOM). Susceptible only to FQ. Caused bad outcomes (compared to what?) But this is just a case series… Can we conclude that the bad outcomes are related to it being resistant? Can we conclude that due to the emergence of this MDR clone we will observe worse outcomes? Yet, it is an important descriptive study.

CA-MRSA with no identified predisposing risk / Herold et al. JAMA 1998 Design: Retrospective review of medical records Objective: To determine whether community-acquired MRSA infections in children with no identified predisposing risks are increasing and to define the spectrum of disease associated with MRSA isolation. Case series and descriptive studies may be of great importance. Controlled studies should follow.

Study designs used to define the impact of Ab resistance: Descriptive studies Case-control studies Cohort studies Meta-analysis Mathematical models

Case-control / Cohort studies confusing terms Health / economical outcomes Resistance Risk factors: Ward Time Time in hospital comorbidities Ab rx IC measures OutcomeExposure OutcomeExposure Vs. Who?

Resistant bacteria compared to what??? what is the counterfactual? The control group –Patients infected by resistant strains (cases) vs. susceptible strains (controls) –Assesses the independent impact of the acquisition of a resistance determinant. –Patients infected by resistant strains (cases) vs. patients w/o resistant strains (controls) –Assesses the burden of having resistant infection Two different questions! a2a1b2b MRSA MSSA

Confounders Health / economical outcomes Resistance Risk factors: Ward Time LOS Comorbidities Ab rx IC measures OutcomeExposure

Confounders: direction of bias they induce Time Bias in either direction LOS / comorbidities Bias towards worse outcome (away from the null) VREMortality Very sick (comorbidities)

Which outcomes? Defining the outcomes Mortality –Distinguish all cause mortality from disease- specific mortality –In-hospital vs. post-discharge mortality Morbidity - more difficult to define –Clinical failure –Length of stay in hospital –Need for surgery Economic outcomes (hospital costs vs. charges vs. resource used)

Health & Economic outcomes of VRE / Carmeli Arch Inter Med 2002 Design: Retrospective Matched cohort study 233 cases of VRE infections 647 controls matched by (randomly picked from the cohort): –Place (Hospital ward) –Time (calendar day) –Duration of hospital stay till infection

Outcomes –Mortality - ICU admission –LOS - Surgery –Hospital Costs - discharge to institution To control for confounding: –Propensity score (RF for being VRE) –CVD, ID, DM, transplantation, MRSA, C. difficile, Ab Rx: 3 rd cephalosporins Health & Economic outcomes of VRE / Carmeli Arch Inter Med 2002

OutcomeCases (n=233) Controls (n=647) RR (95%ci) Attributable to VRE P-value Mortality % ( ) 6.4 LOS mean d ( ) 6.2<.001 Cost mean $ ( ) 12766<.001 Surgery % ( ) ICU admission % ( ) 11<.001 Discharge to institution % ( )

But they did not compare to VSE What is the right control? What does this tell us? What would be the counterfactual of not having VRE?

Study designs used to define the impact of Ab resistance: Descriptive studies Case-control studies Cohort studies Meta-analysis Mathematical models

Meta-analysis “an objective review of the literature” A statistical method for combining information from independent studies to derive an overall estimate (a summary estimate). Great appeal: response to treatments may vary among individuals and different studies Main problems: –Publication bias –Varying quality of the studies –Are we not adding apples and oranges? Did all studies measure the outcome similarly? Did they adjust for the same confounders?

Comparison of mortality associated with MRSA vs. MSSA / Cosgrove et al. CID 2002 Included studies that did not exclude CA- MRSA. Most studies did not adjust for LOS. Subset of 11 studies with adjustment to LOS - no different results.

Meta-analysis VRE vs. VSE / DiazGranados et al. CID 2005 Limitations: Most studies retrospective (leading to inaccurate/incomplete data) Most studies in pre-linezolid, dalfopristin-quinupristin (Synercid) era (no appropriate treatment for VRE): external validity for the current environment? Did not adjust for LOS, but only for comorbidities

Meta-analysis PNSSP vs. PSSP CID 2006 Tleyjeh et al Raised a lot of controversy. In contrast to “conventional wisdom” Same criticism: not all studies adjusted for confounding factors. How was quality of the studies assessed? Resistance & virulence not linked in PRSP

Concordant vs. non- concordant Rx. analysis resulted in same RR.